Get all the updates for this publication
Articles
Regulatory T cell immunotherapy for type 1 diabetes: A step closer to success?Published in Cell Press
2016
PMID: 26863486
Volume: 23
Issue: 2
Pages: 231 - 233
Regulatory T cell (Treg) therapy has shown promises in experimental models of type 1 diabetes (T1D) and other autoimmune diseases. Now, Bluestone et al. (2015) report in a phase 1, dose-escalation study that ex vivo-expanded autologous polyclonal Treg therapy is safe and well tolerated in adult patients with recent-onset T1D. © 2016 Elsevier Inc.
Postprint Version
Content may be subject to copyright,Check License© This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc... ...© This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
About the journal
| Journal | Cell Metabolism |
|---|---|
| Publisher | Cell Press |
| ISSN | 15504131 |
| Open Access | No |
Authors (1)
Jagadeesh Bayry- Restoration of established systemic inflammation and autoimmunity by Foxp3+ regulatory T cells
- Recent advances and prospects of hyaluronan as a multifunctional therapeutic system
- Species-Specific Immunological Reactivities Depend on the Cell-Wall Organization of the Two Aspergillus, Aspergillus fumigatus and A. flavus
- Editorial: The Role of the Fungal Cell Wall in Host-Fungal Interactions
